Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02916771 · OUTCOME

Overall Survival

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma · Source last updated 2025-08-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
years
Interval / dispersion
95% Confidence Interval
Time frame
Time from protocol therapy initiation to death or date last known alive, or up to 60 months post initiation of treatment

What was measured

Overall survival is defined as the time from protocol therapy initiation to death or date last known alive

Groups in this outcome

Ixazomib

* Cycles 1-9 * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle * Lenalidomide is administered orally on days 1-21 on a 28 days cycle * Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle * Cycle 10-24 * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle * Lenalidomide is administered orally on days 1-21 on a 28 days cycle * Supportive measures consistent with optimal patient care may be given throughout the study Ixazomib: Oral, proteasome inhibitor Lenalidomide: Oral, immunomodulatory agent Dexamethasone: Oral, steroid

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ixazomib55

Reported measurements

Source class 1
Values in years · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
IxazomibNANot reportedNANAMedian overall survival was not reached at study completion.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Median overall survival was not reached at study completion.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      55
    units
    Participants
description
Overall survival is defined as the time from protocol therapy initiation to death or date last known alive
dispersion Type
95% Confidence Interval
groups
  1. description
    * Cycles 1-9 * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle * Lenalidomide is administered orally on days 1-21 on a 28 days cycle * Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle * Cycle 10-24 * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle * Lenalidomide is administered orally on days 1-21 on a 28 days cycle * Supportive measures consistent with optimal patient care may be given throughout the study Ixazomib: Oral, proteasome inhibitor Lenalidomide: Oral, immunomodulatory agent Dexamethasone: Oral, steroid
    id
    OG000
    title
    Ixazomib
param Type
MEDIAN
reporting Status
POSTED
time Frame
Time from protocol therapy initiation to death or date last known alive, or up to 60 months post initiation of treatment
title
Overall Survival
type
SECONDARY
unit Of Measure
years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice